Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT05535933 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT05535933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Lead sponsor
Hutchmed
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
September 30, 2022
Completion date
November 30, 2026
Enrollment
111 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

warm antibody autoimmune hemolytic anemia